

RESEARCH ARTICLE

Impact Factor: 7.014

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF UV SPECTROPHOTOMETRIC METHOD FOR SIMULTANEOUS ESTIMATION OF PYRIDOXAMINE DIHYDROCHLORIDE AND ACETYLCYSTEINE IN TABLET DOSAGE FORM.

Sneha Sukadev Ghule*, Ashpak Tamboli, Sagar Kale, Sagar Landage, Snehal Patil Department of Pharmaceutical Chemistry,

Sahyadri College of Pharmacy, Methwade, Sangola, Solapur, Maharashtra, India-413307

*Corresponding Author's E mail: snehaghule02@gmail.com

Received 10 May 2021; Revised 18 May 2021; Accepted 27 May 2021, Available online 10 July 2021.



Cite this article as: Ghule SS, Tamboli A, Kale S, Landage S and Patil S. Analytical method development and validation of UV Spectrophotometric method for simultaneous estimation of Pyridoxamine dihydrochloride and Acetylcysteine in tablet Dosage Form. Asian Journal of Pharmaceutical Education and Research. 2021; 10(3): 30-41.

https://dx.doi.org/10.38164/AJPER/10.3.2021.30-41

ABSTRACT

The present study describes simple, accurate, precise UV spectrophotometric method for the simultaneous estimation of Pyridoxamine dihydrochloride and Acetylcysteine in tablet dosage form. The method involved measurement of absorbance at two wavelengths 220 nm and 216 nm λ max of Pyridoxamine dihydrochloride and Acetylcysteine. Linearity was observed in the range of 2.5microgram/ml to 12.5microgram/ml (r²=0.997) for Pyridoxamine dihydrochloride and 15microgram/ml to 75microgram/ml (r²=0.999) for Acetylcysteine. The percentange mean recovery was found to be 99.26% for Pyridoxamine dihydrochloride and 100.7% for Acetylcysteine. The percentage RSD for the recovery study was less than 2. The methods were validated as per ICH guidelines.

Keywords: Pyridoxamine dihydrochloride, Acetylcysteine, Simultaneous equation, validation, UV spectrophotometer.

INTRODUCTION

Pyridoxamine dihydrochloride chemical name is 4-(aminomethyl)-5-(hydroxymethyl)-2-methylpyridin-3-ol dihydrochloride. Pyaridoxine, pyaridoxal and pyridoxamine are different forms of vitamin B6 that undergo phosphorylation to produce pyridoxal 5-phosphate (PLP). PLP is the co-factor for a large number of enzymes involved in the metabolism of amino acids. Vitamin B6 is available in most food. Although vitamin B6 supplements have become popular in the treatment of nausea in pregnancy, carpal tunnel syndrome and pre-menstrual syndrome, there is no convincing evidence of benefit ¹⁻³.



Figure 1: Structure of Pyridoxamine dihydrochloride

Acetylcysteine is also known as (N-Acetylcysteine or N-acetyl-L-cysteine or NAC) is derived from cysteine by attaching an acetyl group to amino group ⁴. N-Acetylcysteine is an active pharmaceutical agent and nutritional supplement primarily used as a mucolytic agent and in the management of paracetamol overdose. Acetylcysteine it is an antioxidant in its own right but is also deacetylated to cysteine, which participates in the synthesis of the antioxidant glutathione. If you have an allergy to Acetylcysteine or any other part of Acetylcysteine solution.



Figure 2: Structure of Acetylcysteine

From literature survey it was found that no any UV method has been reported on this combination respectively. In this present research work, it was proposed to developed and validate a new, simple, and accurate UV method for simultaneous estimation of Pyridoxamine dihydrochloride and Acetylcysteine in marketed dosage formulations.

In the present work, simultaneous estimation of Pyridoxamine dihydrochloride and Acetylcysteine in combined dosage form is developed and validated as per ICH guideline⁵.

MATERIAL AND METHOD:

Chemicals and Reagents:

Analytical pure sample of Pyridoxamine dihydrochloride and Acetylcysteine were received as a gift sample from Cipla Private Limited were used in the study. The pharmaceutical dosage form used in this

study was NEFROSAVE FORTE labeled to contain Acetylcysteine and Pyridoxamine dihydrochloride 300/50 mg per tablet. The solvent used were of Methanol and Distilled water used in preparation of mobile phase.

Selection of wavelength:

UV spectra of Pyridoxamine dihydrochloride and Acetylcysteine at 220 nm and 216 nm respectively. Mobile phase Methanol: Water (50:50% v/v) is used for this good peaks, good absorbance and better sensitivity. Both drugs absorbed at same point shown in figure 3.



Figure 3: Uv Spectra of Pyridoxamine dihydrochloride & Acetylcysteine

Instrumentation:

A shimadzu 1800UV/VIS double beam spectrophotometer with 1 cm matched quartz cells was used for all spectral measurements ⁶.

Preparation of Mobile phase:

1000 ml mobile phase was prepared by mixing 50 ml methanol and 50 ml distilled water (50:50% v/v).

Preparation of stock solution of Pyridoxamine dihydrochloride:

Prepare a standard stock solution of Pyrodoxamine dihydrochloride by adding 50 mg in 50 ml volumetric flask & make the volume to 50 ml with diluent. Then pipet out 0.1ml and add 10ml volumetric flask and make the volume again 10ml with diluent. (conc. of Pyridoxamine dihydrochloride = 10 microgram/ml).

AJPER July- Sep. 2021, Vol 10, Issue 3 (30-41)

Acetylcysteine:

Prepare a standard stock solution of Acetylcysteine by adding 100 mg in 100 ml volumetric flask & make the volume to 100 ml with diluent. Then pipet out 0.6 ml and add 10 ml volumetric flask and make the volume again 10ml with diluent. (conc. of Acetylcysteine = 60 microgram/ml).

Simultaneous estimation of Pyridoxamine Dihydrochloride and Acetylcysteine:

In simultaneous method we used Absorbances at two selected wavelengths. To determine the λ max of both the drugs we scan in the range of 200-400 nm. Standard solutions of different concentrations of both drugs were prepared in mobile phase. Absorbance of Pyridoxamine dihydrochloride (10microgram/ml) and Acetylcysteine (60 microgram/ml) were recorded at two wavelengths 220 nm and 216 nm by using simultaneous equation method ⁷⁻⁹.

$$Cx = A2ay1 - A1ay2/ax2ay1 - ax1ay2$$

$$Cy = A1ax2 - A2ax1/ax2ay1 - ax1ay1$$

Cx = concentration of Acetylcysteine

Cy = concentration of Pyridoxamine dihydrochloride

ax1and ax2 = absorptivity value of Acetylcysteine at 216nm and 220nm

ay1 and ay2 = absorptivity value of Pyridoxamine dihydrochloride at 216nm and 220nm

A1 = absorbance of standard mixture at 216 nm

A2 = absorbance of standard mixture at 220 nm

Analysis of marketed formulation:

Five tablets of brand name NEFROSAVE FORTE were used. From the five tablets accurately weighed the powder equivalent to single tablet (Pyridoxamine dihydrochloride 50mg and Acetylcysteine 300mg), then transferred to 50 ml volumetric flask to this methanol was added and for dissolving the drug used sonicator approximately for 10 min. then passed it through the whatman filter paper and make up volume up to 50 ml from diluent. From this solution made a 10microgram/ml and 60microgram/ml solution for Pyridoxamine dihydrochloride and Acetylcysteine resepectively ¹⁰⁻¹⁵.

Sr no.	Pyridox	xamine dihydrochlo	oride	Acetylcysteine		
		Amount	%		Amount	%
	Absorbance	recovered	Recovery	Absorbance	recovered	Recovery
		(microgram/ml)			(microgram/ml)	
1	0.290	9.76	97.6	0.333	61.09	101.8
2	0.293	9.86	98.6	0.336	61.42	102.3
3	0.295	9.93	99.3	0.332	60.77	101.2
4	0.297	10	100	0.339	61.26	102.1
5	0.294	9.9	99	0.341	60.93	101.5
Mean	0.293	9.89	98.9	0.336	61.094	101.8
%	0.8810	0.8987	0.8987	1.1404	0.4218	0.4218
RSD						

Table 1: Analysis of marketed formulation

Method validation ¹⁶⁻¹⁷:

Validation of an analytical method is the process to establish that the performance characteristics of the developed method meet the requirements of the intended analytical application. The UV method was validated in terms of linearity, accuracy, precision, LOD and LOQ.

Linearity:

Linearity was studied by plotting a graph of absorbance is directly proportional to the concentration. A series of standard solution of Pyridoxamine dihydrochloride were prepared in the concentration range of about 2.5microgram/ml to 12.5 microgram/ml and Acetylcysteine concentration range is 15 μ g/ml to 75 μ g/ml is shown in below table (2). Linearity graph of Pyridoxamine dihydrochloride and Acetylcysteine shown in fig.no.4 & 5.

	Concentration (1	microgram/ml)	Absor	bance
Sr no.	Pyridoxamine	Acetylcysteine	Pyridoxamine	Acetylcysteine
	dihydrochloride		dihydrochloride	at 216 nm
			at 220nm	
1	2.5	15	0.072	0.090
2	5	30	0.159	0.180
3	7.5	45	0.230	0.269
4	10	60	0.290	0.373
5	12.5	75	0.370	0.448

Table 2: Linearity study of Pyridoxamine Dihydrochloride and Acetylcysteine



Fig 4: linearity graph of Pyridoxamine dihydrochloride





AJPER July- Sep. 2021, Vol 10, Issue 3 (30-41)

Precision:

Repeatability measurement were carried out by analyzing 6 different solutions containing concentration 5, 7.5, 10 μ g/ml of Pyridoxamine dihydrochloride and 30, 45, 60microgram/ml of Acetylcysteine. For determination of intra-day and inter-day variation the absorbance were measured three times in the days. Result of % RSD was found to be below 2 shown in below tables (3,4,5,6).

Conc.		Absorbance		Mean	SD	%RSD	
microgram/ml	Trial Trial		Trial	Absorbance			
	1	2	3				
5	0.164	0.166	0.172	0.717	0.003606	0.5028	
7.5	0.235	0.225	0.239	0.725	0.003055	0.4213	
10	0.312	0.316	0.318	0.815	0.003055	0.3748	

Table 3: Intra-day precision	of Pyridoxamine	dihydrochloride
------------------------------	-----------------	-----------------

Table 4: Intra-day precision of Acetylcysteine

Conc.		Absorbance	!	Mean	SD	%RSD
microgram/ml	Trial	Trial	Trial	Absorbance		
	1	2	3			
30	0.182	0.184	0.185	0.738	0.007839	1.0621
45	0.265	0.270	0.269	0.741	0.007839	1.0578
60	0.375	0.373	0.378	0.753	0.007737	1.0275

Table 5: Inter-day precision of Pyridoxamine dihydrochloride

Conc. Absorband		Absorbance	Mean		SD	%RSD
microgram/ml	Trial	Trial	Trial	Absorbance		
	1	2	3			
5	0.165	0.167	0.173	0.709	0.007435	1.0486
7.5	0.232	0.226	0.238	0.712	0.007396	1.0387
10	0.314	0.315	0.317	0.724	0.002517	0.3475

Conc.		Absorbance		Mean	SD	%RSD	
microgram/ml	microgram/ml Trial Trial Trial		Trial	Absorbance			
	1	2	3				
30	0.184	0.183	0.186	0.184	0.001527	0.8301	
45	0.267	0.269	0.271	0.269	0.002	0.7434	
60	0.371	0.370	0.376	0.372	0.003214	0.8641	

Table 6:Inter-day precision of Acetylcysteine

Accuracy:

This parameter is performed to determine the closeness of the test results with that of the true value which is expressed as % recovery. These studies were performed at three different levels (50%, 100%, and 150%) and the % recovery of Pyridoxamine dihydrochloride and Acetylcysteine was calculated below table (7& 8).

Level	Conc.(microgram/ml)		Absorbance	% Recovery	Mean %
	Sample	Standard			recovery
					±RSD
			0.434	99.26	
50%	10	5	0.438	100.2	99.73±0.4712
			0.436	99.73	
			0.564	96.85	
100%	10	10	0.562	96.55	96.53±0.3370
			0.560	96.2	
			0.722	99.28	
150%	10	15	0.724	99.56	99.56±0.2812
			0.726	99.84	

Table 7: Recovery study of Pyridoxamine dihydrochloride

Level	Conc.(mic	rogram/ml)	Absorbance	% Recovery	Mean %
	Sample	Standard			recovery
					±RSD
			0.139	100.7	
50%	15	7.5	0.140	101.4	100.7±0.6951
			0.138	100	
			0.182	99.43	
100%	15	15	0.184	100.5	100.3±0.8430
			0.185	101.1	
			0.226	99.09	
150%	15	22.5	0.228	100	99.25±0.6893
			0.225	98.66	

Table 8: Recovery study of Acetylcysteine

Robustness:

The robustness of the analytical method is measure of its capacity to remain unaffected by small but deliberate variations in the method parameters and provides an indication of its reliability during normal usage. The robustness of the method was studied for Pyridoxamine dihydrochloride and Acetylcysteine.

Sensitivity:

The limit of detection [LOD] and limit of quantitation [LOQ] parameters were calculated using following equations; LOD = $3.3\sigma/S$ and LOQ = $10 \sigma/S$

Where, σ = standard deviation of y-intercept of regression line.

S= slope of the calibration curve.

Limit of Detection (LOD) and Limit of Quantitation (LOQ) Determination:

Limit of quantitation is 3 times more than the limit of detection resp. The LOD value of Pyridoxamine dihydrochloride and Acetylcysteine is 4.60 microgram/ml and 19.78 microgram/ml respectively and the LOQ value were found to be 13.96 microgram/ml and 59.95 microgram/ml Pyridoxamine dihydrochloride and Acetylcysteine.

Sr no.	Name of drugs	LOD	LOQ
		(microgram/ml)	(microgram/ml)
1	Pyrodoxamine dihydrochloride	4.60	13.96
2	Acetylcysteine	19.78	59.95

Table 9: Result of LOD AND LOQ

RESULT AND DISCUSSION:

The proposed method is based on spectrophotometric simultaneous estimation of Pyridoxamine dihydrochloride and Acetylcysteine in this method methanol and distilled water is used as solvent. the calibration plot for the method was linearity range concentration of 15 to 75microgram/ml for Acetylcysteine and 2.5 to 12.5microgram/ml for Pyridoxamine dihydrochloride respectively. The determination of coefficients (r²) was 0.999 and 0.997 for Acetylcysteine and Pyridoxamine dihydrochloride respectively. The method was found to be precise and as the %RSD values for intra-day and inter-day were found to be less than 2% for Acetylcysteine and Pyridoxamine dihydrochloride respectively. The LOD and LOQ were found to be 19.78 microgram/ml and 59.95 microgram/ml for Acetylcysteine and 4.6 0 microgram/ml and 13.96 microgram/ml for Pyridoxamine dihydrochloride respectively. The percentange mean recovery was found to be 99.26% for Pyridoxamine dihydrochloride and 100.7 % for Acetylcysteine. The results of assay showed that the amount of drug as indicated by % assay for 101.8 % Acetylcysteine and 98.9 % for Pyridoxamine dihydrochloride. The proposed method was also successfully applied to a pharmaceutical formulation¹⁸⁻¹⁹.

CONCLUSION:

The results of our study indicate that the proposed UV spectroscopic method is simple, rapid, precise, and accurate. The developed UV spectroscopic methods were found suitable for determination of Pyridoxamine dihydrochloride and Acetylcysteine as bulk drug and in marketed solid dosage formulation without any interference from the excipients. Statistical analysis proves that, these methods are repeatable and selective for the analysis of Pyridoxamine dihydrochloride and Acetylcysteine.

ACKNOWLEDGEMENT:

I am very much thankful to sahyadri college of pharmacy, Methwade (Sangola), Maharashtra, for giving permission to carry out my work.

References :

- Bharathi D, Saranya D, Sharmila S, Varsha R, Nandhini P and Reddy PS. Development and validation of RP-HPLC method for simultaneous estimation of pyrodoxamine dihydrochloride and actylcysteine in tablet dosage form. International journal of medicinal chemistry and analysis. 2016; 6(2): 94-99.
- United States Pharmacopeial convention: United States Pharmacopoeia 36; National Formulary 31, US Pharmacopoea Convention, Rockville, MD, 2013.
- **3.** Athawale R, Nadkar S, Phadtare P and Naik S. Development and Validation of RP-HPLC Method for the Estimation of NAcetylcysteine in Wet Cough syrup. International Journal of Drug Development & Research. 2012; 4(2):284-293.
- **4.** British Pharmacopoeia. Introduction General Notice Monograph, Medicinal and Pharmaceutical substances (A1). 2004; 45.
- 5. ICH validation of analytical procedures: text and, methodology Q2(R1), 2005.
- Jeyaraman AI. Venkateshan N and Devi M. Analytical Method Development and Validation of Acetylcysteine and Taurinein Tablet Dosage Form by Using RP-HPLC. Indo American Journal of Pharmaceutical Sciences. 2018; 5(1): 717-726.
- Kumar M, Jindal M, Bhatt S, Pandurangan A, Malik A and Kaushik V. Simultaneous Estimation of Amlodipine Besylate and Ramipril in Tablets Dosage Form by UV Spectrophotometric Method. Journal of Pharmaceutical Sciences and Research. 2019; 11(2): 667-670.
- Amrutkar S, Derle D, Kulkarni S and Derle N. RP-HPLC Method Development and Validation for Simultaneous Estimation of Paracetamol and N-Acetylcystine in its Bulk and Effervescent Tablet Dosage Form. Indo American Journal of Pharmaceutical Research. 2017; 7(2):7661-7670.
- 9. Lalitha KG and Jadhav N. Development and Validation of Spectroscopic Method for Simultaneous Estimation of Acebrophylline and Acetylcysteine in Capsule Dosage Form. International Journal of Pharmaceutical and Phytopharmacological Research. 2014; 4 (2): 113-115.
- 10. More S, Tamboli A and Patil S. UV Spectrophotometric Methods for the Simultaneous Estimation of Pregabalin and Amitriptyline Hydrochloride in Combined Tablet Dosage Form, International Journal of Pharmacy and Pharmaceutical Research. 2019; 15(3):15-24.

AJPER July- Sep. 2021, Vol 10, Issue 3 (30-41)

- **11.** Begum A. Development and Validation of Acetylcysteine and Taurine in Tablet Dosage Form by RP-HPLC. International Journal of Universal Pharmacy and Bio Sciences. 2014; 3(5):11-24.
- 12. Patel T, Prajapati L, Joshi A and Kharodiya M. Q-Absorbance Ratio Method for Simultaneous Estimation of Acetylcysteine and Acebrophylline. World Journal of Pharmaceutical Research. 2015;4(5):1808-1816.
- 13. Rele R. Simultaneous spectrophotometric estimation of Paracetamol and Aceclofenac by second order derivative method in combined dosage form. Journal of Chemical and Pharmaceutical Research. 2015; 7(6):512-517.
- 14. Jothieswari D. A Validated UV Spectrophotometric Method for the Simultaneous Estimation of Amlodipine Besylate, Valsartan and Hydrochlorothiazide in Bulk and in Combined Tablet Dosage Form. Journal of Pharmaceutical and Biomedical Sciences. 2010; 5(5):1-5.
- 15. Karunakarana A, Premkumara S, Murugesana V, Munusamya J and Murugesanb R, Validated UV-Spectrophotometric Method for the Simultaneous Estimation of Pyridoxine Hydrochloride and Doxylamine Succinate in Bulk and in Pharmaceutical Dosage form. Advanced Journal of Chemistry-Section A., 2019; 2(3): 245-255.
- 16. Kathirvel S, Indukala PC, Mohan S, Gayathri RM and Rajesh A, New Stability Indicating RP-HPLC Method for Simultaneous Estimation of Acebrophylline and N-Acetylcysteine in Tablet Dosage Form and Its Validation as Per ICH Guidelines. International journal of pharmacy and pharmaceutical research. 2019; 16 (2): 422-435.
- 17. Sangeetha P. Validated UV-spectrophotometric method for the simultaneous estimation of pyridoxamine hydrochloride and doxylamine succinate in bulk and in pharmaceutical dosage form. Advanced journal of chemistry. 2019;2(3):245-255.
- Tripathi KD. Essentials of Medical Pharmacology; 6th Edn; Jaypee Brother's Medical Publishers Ltd, New Delhi, 2010: 214-216.
- **19.** Beckett AH and Stenlake JB. Practical Pharmaceutical chemistry, 4th edition, part 2.1997.